ClinicalTrials.gg
CompletedNCT03193190Updated Nov 21, 2025Results posted

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

A Phase 1/2 interventional study of Nab-Paclitaxel and Gemcitabine in Pancreatic Adenocarcinoma, sponsored by Hoffmann-La Roche. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.

02

Conditions studied

  • Pancreatic Adenocarcinoma
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0 or 1
  • or cytologically confirmed pancreatic ductal adenocarcinoma
  • For patients in Cohort 1: no prior systemic treatment for PDAC
  • For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based chemotherapy
  • greater than or equal to 3 months
  • Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 () and/or additional biomarker status via central testing
  • (at least one target lesion) according to v1.1
  • Adequate hematologic and end-organ function test results
  • Tumor accessible for
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month)
  • Symptomatic, untreated, or actively progressing central nervous system (CNS)
  • History of
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Positive human immunodeficiency () test at screening or at any time prior to screening
  • Active or C virus infection or active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Prior allogeneic stem cell or solid organ transplantation
  • History of other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
341 participants (actual)

Study arms

  • Active comparator
    Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)

    Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle. Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine

  • Experimental
    Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab

    Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Selicrelumab

  • Experimental
    Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab

    Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Bevacizumab

  • Experimental
    Cohort 1: Atezolizumab + Chemotherapy + AB928

    Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: AB928

  • Experimental
    Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab

    Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Tiragolumab

  • Experimental
    Cohort 2: Atezolizumab + Cobimetinib

    Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment.

    Drug: Atezolizumab · Drug: Cobimetinib

  • Experimental
    Cohort 2: Atezolizumab + PEGPH20

    Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

    Drug: Atezolizumab · Drug: PEGPH20

  • Experimental
    Cohort 2: Atezolizumab + BL-8040

    Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

    Drug: Atezolizumab · Drug: BL-8040

  • Experimental
    Cohort 2: Atezolizumab + RO6874281 every 2 weeks

    Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.

    Drug: Atezolizumab · Drug: RO6874281

  • Experimental
    Cohort 2: Atezolizumab + RO6874281 every 3 weeks

    Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.

    Drug: Atezolizumab · Drug: RO6874281

  • Active comparator
    Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)

    Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle. Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m\^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m\^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m\^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m\^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil

  • Experimental
    Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab

    Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.

    Drug: Nab-Paclitaxel · Drug: Gemcitabine · Drug: Atezolizumab · Drug: Tocilizumab

Interventions

  • Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

  • Gemcitabine will be administered as per the schedule specified in the respective arm.

  • Oxaliplatin will be administered as per the schedule specified in the respective arm.

  • Leucovorin will be administered as per the schedule specified in the respective arm.

  • Fluorouracil will be administered as per the schedule specified in the respective arm.

  • Atezolizumab will be administered as per the schedule specified in the respective arm.

  • Cobimetinib will be administered as per the schedule specified in the respective arm.

  • PEGPH20 will be administered as per the schedule specified in the respective arm.

  • BL-8040 will be administered as per the schedule specified in the respective arm.

  • Selicrelumab will be administered as per the schedule specified in the respective arm.

  • Bevacizumab will be administered as per the schedule specified in the respective arm.

  • RO6874281 will be administered as per the schedule specified in the respective arm

  • DrugAB928

    AB928 will be administered as per the schedule specified in the respective arm.

  • Tiragolumab will be administered as per the schedule specified in the respective arm.

  • Tocilizumab will be administered as per the schedule specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off.

    Time frame: Up to 33.3 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: Up to 33.3 months

  2. Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1

    PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier (K-M) method was used to estimate PFS.

    Time frame: Up to 33.3 months

  3. Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1

    OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS.

    Time frame: Up to 33.3 months

  4. Stage 1: OS Rate at Month 6

    OS was defined as the time from randomization to death from any cause. OS rate at 6 months was defined as the percentage of participants who did not experience death from any cause at 6 months from randomization. K-M method was used to estimate OS. Percentages have been rounded off.

    Time frame: Month 6

  5. Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1

    DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR=the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate DOR.

    Time frame: Up to 33.3 months

  6. Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1

    DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Percentages have been rounded off.

    Time frame: Up to 33.3 months

07

Results

Posted Nov 21, 2025

Participant flow

A total of 341 participants with metastatic pancreatic ductal adenocarcinoma (PDAC) took part in the study from 05 Jul 2017 to 27 Feb 2025. The study included participants in 2 cohorts: Cohort 1: received no prior systemic therapy for metastatic PDAC \& Cohort 2: received 1 prior line of systemic therapy for PDAC. Multiple combination therapies were compared against common control(s) in Cohorts 1 and 2.

Stage 1
Participant flow — Stage 1
MilestoneStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 3 Weeks (Q3W)Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 2 Weeks (Q2W)Stage 2 Cohort 2: Atezolizumab + CobimetinibStage 2 Cohort 2: Atezolizumab + RO6874281 Q3WStage 2 Cohort 2: Atezolizumab + RO6874281 Q2W
Started3592516423125251615711615000
Safety population3292515413023231514661514000
Completed0000000000000000
Not completed3592516423125251615711615000
Withdrew: Arm terminated by sponsor0001020000000000
Withdrew: Death2282314342819211410591414000
Withdrew: Lost to follow-up2110001000000000
Withdrew: Reason not specified1001012201301000
Withdrew: Physician decision0000000000010000
Withdrew: Progressive disease1000000000000000
Withdrew: Study terminated by sponsor3000600000000000
Withdrew: Withdrawal by subject6010203224910000
Stage 2
Participant flow — Stage 2
MilestoneStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 3 Weeks (Q3W)Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 2 Weeks (Q2W)Stage 2 Cohort 2: Atezolizumab + CobimetinibStage 2 Cohort 2: Atezolizumab + RO6874281 Q3WStage 2 Cohort 2: Atezolizumab + RO6874281 Q2W
Started00000000000001561
Safety population00000000000001461
Completed0000000000000000
Not completed00000000000001561
Withdrew: Death00000000000001441
Withdrew: Lost to follow-up0000000000000010
Withdrew: Withdrawal by subject0000000000000110

Outcome measures

PrimaryStage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off.

Time frame:
Up to 33.3 months
Reported as:
Number · percentage of participants
Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
percentage of participantsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2W
Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)37.5 (21.10 to 56.31)55.6 (21.20 to 86.30)48.0 (27.80 to 68.69)26.7 (7.79 to 55.10)31.7 (18.08 to 48.09)30.0 (14.73 to 49.40)8.7 (1.07 to 28.04)0 (0.00 to 14.82)0 (0.00 to 23.16)0 (0.00 to 23.16)6.1 (1.68 to 14.80)0 (0.00 to 21.80)7.1 (0.18 to 33.87)
Statistical analysis
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab · Difference in orr: 18.06 · 95% CI -25.60 to 61.71
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab · Difference in orr: 10.50 · 95% CI -18.85 to 39.85
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 · Difference in orr: -10.83 · 95% CI -43.70 to 22.03
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab · Difference in overall response rates: -5.79 · 95% CI -30.58 to 18.99
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab · Difference in orr: -7.50 · 95% CI -34.19 to 19.19
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040 · Difference in orr: -8.70 · 95% CI -25.96 to 8.57
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib · Difference in overall response rates: -8.70 · 95% CI -25.96 to 8.57
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20 · Difference in orr: -2.64 · 95% CI -18.44 to 13.17
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W · Difference in orr: -8.70 · 95% CI -25.72 to 8.33
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W · Difference in orr: -1.55 · 95% CI -25.04 to 21.93
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

Time frame:
Up to 33.3 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WStage 2 Cohort 2: Atezolizumab + CobimetinibStage 2 Cohort 2: Atezolizumab + RO6874281 Q3WStage 2 Cohort 2: Atezolizumab + RO6874281 Q2W
Number of Participants With Adverse Events (AEs)32924154130222315146515141460
SecondaryStage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1

PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier (K-M) method was used to estimate PFS.

Time frame:
Up to 33.3 months
Reported as:
Median · months
Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1
monthsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2W
Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.16.11 (5.13 to 9.92)4.04 (3.02 to 6.97)7.18 (5.03 to 9.82)8.21 (5.91 to 11.10)5.82 (4.40 to 7.52)5.39 (4.17 to 8.21)2.76 (1.45 to 5.52)2.53 (1.77 to 4.04)1.64 (1.41 to 1.87)1.28 (1.15 to 1.84)1.51 (1.38 to 2.56)1.38 (1.38 to 2.66)1.46 (1.31 to 1.58)
Statistical analysis
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab · Hazard ratio (hr): 1.12 · 95% CI 0.48 to 2.64
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab · Hazard ratio (hr): 1.17 · 95% CI 0.66 to 2.08
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 · Hazard ratio (hr): 0.60 · 95% CI 0.29 to 1.23
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab · Hazard ratio (hr): 1.13 · 95% CI 0.67 to 1.89
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab · Hazard ratio (hr): 1.07 · 95% CI 0.61 to 1.87
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040 · Hazard ratio (hr): 2.13 · 95% CI 0.96 to 4.75
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib · Hazard ratio (hr): 3.63 · 95% CI 1.54 to 8.57
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20 · Hazard ratio (hr): 1.15 · 95% CI 0.68 to 1.92
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W · Hazard ratio (hr): 1.48 · 95% CI 0.72 to 3.05
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W · Hazard ratio (hr): 1.74 · 95% CI 0.84 to 3.06
SecondaryStage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1

OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS.

Time frame:
Up to 33.3 months
Reported as:
Median · months
Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1
monthsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2W
Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.114.55 (9.99 to 16.16)9.03 (3.42 to 16.13)13.34 (9.10 to 15.21)16.49 (9.59 to 19.71)13.34 (9.43 to 21.59)11.20 (8.21 to 17.94)6.77 (6.34 to 9.66)8.31 (4.11 to 13.04)4.47 (3.12 to 7.06)4.24 (1.84 to 6.97)7.06 (4.07 to 8.38)4.70 (3.81 to 11.04)7.33 (4.86 to 11.60)
Statistical analysis
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab · Hazard ratio (hr): 1.33 · 95% CI 0.59 to 3.00
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab · Hazard ratio (hr): 1.28 · 95% CI 0.71 to 2.29
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 · Hazard ratio (hr): 0.89 · 95% CI 0.45 to 1.74
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab · Hazard ratio (hr): 0.98 · 95% CI 0.58 to 1.68
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab · Hazard ratio (hr): 1.04 · 95% CI 0.59 to 1.84
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040 · Hazard ratio (hr): 2.04 · 95% CI 0.87 to 4.77
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib · Hazard ratio (hr): 1.32 · 95% CI 0.60 to 2.94
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20 · Hazard ratio (hr): 0.88 · 95% CI 0.48 to 1.60
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W · Hazard ratio (hr): 1.51 · 95% CI 0.68 to 3.36
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W · Hazard ratio (hr): 0.94 · 95% CI 0.44 to 2.02
SecondaryStage 1: OS Rate at Month 6

OS was defined as the time from randomization to death from any cause. OS rate at 6 months was defined as the percentage of participants who did not experience death from any cause at 6 months from randomization. K-M method was used to estimate OS. Percentages have been rounded off.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Stage 1: OS Rate at Month 6
percentage of participantsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2W
Stage 1: OS Rate at Month 687.07 (75.23 to 98.91)55.56 (23.09 to 88.02)83.48 (68.67 to 98.28)80.00 (59.76 to 100.00)72.55 (58.72 to 86.37)86.67 (74.50 to 98.83)78.76 (60.06 to 97.46)53.45 (30.72 to 76.19)27.78 (1.17 to 54.39)41.96 (14.01 to 69.91)51.97 (39.29 to 64.65)43.33 (17.35 to 69.32)50.00 (23.81 to 76.19)
Statistical analysis
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab · Difference in event free rate: -31.51 · 95% CI -66.07 to 3.04
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab · Difference in event free rate: -3.59 · 95% CI -22.55 to 15.37
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 · Difference in event free rate: -7.07 · 95% CI -30.52 to 16.38
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab · Difference in event free rate: -14.52 · 95% CI -32.72 to 3.68
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab · Difference in event free rate: -0.40 · 95% CI -17.38 to 16.57
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040 · Difference in event free rate: -50.98 · 95% CI -83.51 to -18.46
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib · Difference in event free rate: -36.80 · 95% CI -70.43 to -3.18
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20 · Difference in event free rate: -26.79 · 95% CI -49.39 to -4.20
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W · Difference in event free rate: -35.43 · 95% CI -67.44 to -3.42
  • Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W · Difference in event free rate: -28.76 · 95% CI -60.94 to 3.42
SecondaryStage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1

DOR was defined as time from first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurs first as determined by investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR=the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR=at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate DOR.

Time frame:
Up to 33.3 months
Reported as:
Median · months
Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1
monthsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2W
Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.15.40 (3.94 to 8.21)3.35 (2.56 to NA)8.18 (6.34 to 8.74)4.85 (2.86 to NA)4.47 (3.58 to 10.12)5.65 (4.53 to 10.84)3.37 (2.83 to NA)———8.15 (5.32 to NA)—6.14 (NA to NA)
Statistical analysis
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab · Hazard ratio (hr): 0.91 · 95% CI 0.24 to 3.51
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab · Hazard ratio (hr): 0.60 · 95% CI 0.23 to 1.60
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 · Hazard ratio (hr): 1.56 · 95% CI 0.44 to 5.47
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab · Hazard ratio (hr): 0.92 · 95% CI 0.35 to 2.44
  • Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab · Hazard ratio (hr): 0.69 · 95% CI 0.24 to 1.93
SecondaryStage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1

DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Percentages have been rounded off.

Time frame:
Up to 33.3 months
Reported as:
Number · percentage of participants
Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1
percentage of participantsStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2W
Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.181.3 (63.56 to 92.79)55.6 (21.20 to 86.30)64.0 (42.52 to 82.03)66.7 (38.38 to 88.18)61.0 (44.50 to 75.80)66.7 (47.19 to 82.71)30.4 (13.21 to 52.92)34.8 (16.38 to 57.27)0 (0.00 to 23.16)0 (0.00 to 23.16)18.2 (9.76 to 29.61)0 (0.00 to 21.80)7.1 (0.18 to 33.87)

Adverse events

Collected over Up to 33.3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)23/32 (71.9%)13/32 (40.6%)32/32 (100%)
Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab8/9 (88.9%)8/9 (88.9%)9/9 (100%)
Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab23/25 (92%)17/25 (68%)23/25 (92%)
Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB92814/15 (93.3%)4/15 (26.7%)15/15 (100%)
Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab34/41 (82.9%)19/41 (46.3%)40/41 (97.6%)
Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab28/30 (93.3%)12/30 (40%)30/30 (100%)
Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])19/23 (82.6%)10/23 (43.5%)21/23 (91.3%)
Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)21/23 (91.3%)12/23 (52.2%)23/23 (100%)
Stage 1 Cohort 2: Atezolizumab + BL-804014/15 (93.3%)4/15 (26.7%)15/15 (100%)
Stage 1 Cohort 2: Atezolizumab + Cobimetinib11/14 (78.6%)8/14 (57.1%)13/14 (92.9%)
Stage 1 Cohort 2: Atezolizumab + PEGPH2060/66 (90.9%)30/66 (45.5%)65/66 (98.5%)
Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W14/15 (93.3%)7/15 (46.7%)15/15 (100%)
Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W14/14 (100%)2/14 (14.3%)14/14 (100%)
Stage 2 Cohort 2: Atezolizumab + Cobimetinib14/14 (100%)7/14 (50%)13/14 (92.9%)
Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W5/6 (83.3%)2/6 (33.3%)6/6 (100%)
Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W1/1 (100%)0/1 (0%)0/1 (0%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WStage 2 Cohort 2: Atezolizumab + CobimetinibStage 2 Cohort 2: Atezolizumab + RO6874281 Q3WStage 2 Cohort 2: Atezolizumab + RO6874281 Q2W
PyrexiaGeneral disorders1/323/90/250/151/410/301/234/230/151/143/662/150/141/140/60/1
Atrial fibrillationCardiac disorders0/322/90/250/150/410/301/230/230/150/140/660/150/140/140/60/1
PneumoniaInfections and infestations2/322/90/250/153/411/300/230/231/150/140/660/150/141/140/60/1
Abdominal painGastrointestinal disorders0/320/91/252/152/411/301/230/230/150/142/660/150/140/141/60/1
ArthralgiaMusculoskeletal and connective tissue disorders0/320/90/250/150/410/300/230/230/150/140/660/150/140/141/60/1
Acute kidney injuryRenal and urinary disorders0/321/93/250/150/411/300/230/230/150/140/661/150/141/140/60/1
Abdominal distensionGastrointestinal disorders0/321/90/250/150/410/300/230/230/150/140/660/150/140/140/60/1
Retroperitoneal haemorrhageGastrointestinal disorders0/321/90/250/150/410/300/230/230/150/140/660/150/140/140/60/1
ChillsGeneral disorders0/321/90/250/150/410/300/230/230/150/141/660/150/140/140/60/1
Influenza like illnessGeneral disorders0/321/90/250/150/410/300/230/230/150/140/660/150/140/140/60/1
Most frequent other events
Showing 10 of 267
Most frequent other events
EventStage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WStage 2 Cohort 2: Atezolizumab + CobimetinibStage 2 Cohort 2: Atezolizumab + RO6874281 Q3WStage 2 Cohort 2: Atezolizumab + RO6874281 Q2W
NauseaGastrointestinal disorders17/327/99/257/1521/4116/3010/239/235/157/1420/666/159/142/143/60/1
Injection site reactionGeneral disorders0/324/90/250/150/410/300/230/2311/150/141/660/150/140/140/60/1
PyrexiaGeneral disorders11/325/93/253/1514/412/301/235/232/155/147/667/1510/142/143/60/1
MyalgiaMusculoskeletal and connective tissue disorders4/324/93/250/155/415/301/232/230/150/1445/660/152/140/140/60/1
ChillsGeneral disorders0/323/92/250/155/410/300/231/230/151/141/6610/156/141/142/60/1
FatigueGeneral disorders18/325/911/253/1523/417/305/239/2310/155/1421/665/156/142/142/60/1
AnaemiaBlood and lymphatic system disorders14/324/910/259/1513/416/304/236/233/152/148/661/151/143/142/60/1
Neutrophil count decreasedInvestigations6/324/98/255/1510/4118/303/238/230/150/142/660/150/140/140/60/1
Injection related reactionInjury, poisoning and procedural complications0/320/90/250/150/410/300/230/238/150/140/660/150/140/140/60/1
Platelet count decreasedInvestigations4/323/94/254/1511/4116/302/234/230/150/141/664/151/140/140/60/1

Baseline characteristics

Intent to treat (ITT) population included all randomized participants.

Age, Customized
Age, Customized(Participants)Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WTotal
18-64 years15613112611920894988193
65-84 years2031251620165862287148
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WTotal
Female1347812111411552897134
Male2251883020111411104378207
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WTotal
Hispanic or Latino101050010030112
Not Hispanic or Latino3392316363025241615681614325
Unknown or Not Reported10101100000004
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 1: Atezolizumab + Chemotherapy + SelicrelumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + BevacizumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928Stage 1 Cohort 1: Atezolizumab + Chemotherapy + TiragolumabStage 1 Cohort 1: Atezolizumab + Chemotherapy + TocilizumabStage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6])Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine)Stage 1 Cohort 2: Atezolizumab + BL-8040Stage 1 Cohort 2: Atezolizumab + CobimetinibStage 1 Cohort 2: Atezolizumab + PEGPH20Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3WStage 1 Cohort 2: Atezolizumab + RO6874281 Q2WTotal
American Indian or Alaska Native01000000001002
Asian12158812116842163105
Native Hawaiian or Other Pacific Islander00000000000011
Black or African American02111100120009
White1841673015141979431011203
More than one race00100000000001
Unknown or Not Reported512033000060020
08

Study locations

23 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Helen Diller Fam Comp Can Ctr
    San Francisco, California 94158, United States
  • Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06510, United States
  • Lombardi Cancer Center, Georgetown University
    Washington D.C., District of Columbia 20007, United States
  • Uni of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • MorristownMedicalCenter
    Morristown, New Jersey 07962, United States
  • Columbia University
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Universitätsklinikum Essen
    Essen, 45122, Germany
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • Kanagawa Cancer Center
    Kanagawa, 241-8515, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Clínica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Universitario Vall d Hebron
    Barcelona, 08035, Spain
  • Hosp. G. U Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28037, Spain
09

References and documents

Publications

  • Ko AH, Oh DY, Lau J, Mhatre SK, Ci B, Machado R, Li S, Bretscher MT, Reyes-Rivera I, Zhu J, Zhang X, Patel J, Psioda MA, Ponz-Sarvise M. Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. Clin Pharmacol Ther. 2025 Apr;117(4):1021-1029. doi: 10.1002/cpt.3528. Epub 2024 Dec 20. PubMed 39707623 ↗
  • Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023 Jun 2;28(6):553-e472. doi: 10.1093/oncolo/oyad022. PubMed 36940261 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Feb 2025, 91 months.

Results were first posted in Nov 2025, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2017
First posted
Jun 20, 2017
StartActual
Jul 5, 2017
Primary completionActual
Feb 27, 2025
CompletionActual
Feb 27, 2025
Results first posted
Nov 21, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03193190
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 20, 2017
Start date
Jul 5, 2017
Primary completion
Feb 27, 2025
Completion
Feb 27, 2025
Results posted
Nov 21, 2025
Last update
Nov 21, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine · Cobimetinib · PEGPH20 · Motixafortide · Selicrelumab · Bevacizumab · Simlukafusp alfa · AB928 · Tiragolumab · Tocilizumab

Start the discussion